Mar 26 |
How Much Upside is Left in Oric Pharmaceuticals (ORIC)? Wall Street Analysts Think 39.3%
|
Mar 13 |
ORIC Pharmaceuticals: Mid-2024 Prostate Cancer Program Update Could Lead To Gains
|
Mar 13 |
ORIC Pharmaceuticals Inc (ORIC) Reports Q4 and Full Year 2023 Financial Results
|
Mar 11 |
ORIC Pharmaceuticals files for automatic mixed securities shelf
|
Mar 11 |
ORIC Pharmaceuticals GAAP EPS of -$0.49
|
Mar 11 |
ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Updates
|
Mar 8 |
ORIC Pharmaceuticals Inc CEO Jacob Chacko Sells 40,000 Shares
|
Mar 6 |
ORIC Pharmaceuticals to Present at the Leerink Partners Global Biopharma Conference
|
Mar 5 |
ORIC Pharmaceuticals Announces Multiple Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting
|
Mar 1 |
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
|